An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Enzalutamide (Primary) ; Degarelix; Goserelin; Histrelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Adverse reactions
- 21 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.